Navigation Links
Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
Date:1/31/2013

OSLO, January 31, 2013 /PRNewswire/ --

18-24 patients will be included in the clinical Phase I/II study. Results from the Phase I part are expected in first half of 2013.

Principal investigator and oncologist Svein Dueland states: "It is exciting that we now recruit patients for this study, which originates from collaboration between Oslo University Hospital and Norsk Hydro. Participation in clinical trials is an important part of the treatment we can offer cancer patients."

Hanne Mette D Kristensen, CEO, says: "We are proud that Targovax now has its first drug in clinical Phase I/II, only two years after the company's inception. The study will run at the Radium Hospital at Oslo University Hospital, international pioneers in development of immunotherapy and cancer vaccines. TG01 has already shown promising results in patients. If these results are confirmed by systematic studies, TG01 may mean the first real change for pancreatic cancer patients."

Targovax is owned by The Radium Hospital Research Foundation, Birk Venture and RO Invest, inventors and management. The company has received grant from Innovation Norway for running the clinical Phase I/II trial in collaboration with OUS, The Radium Hospital.

Targovax

Targovax is a cancer biotech-company started in October 2010. The TG01 cancer vaccine is therapeutic; it is given as treatment to patients who already have cancer to prevent recurrence, and educates the body's immune system to recognize and kill cancer cells.

Approximately 80-90% of pancreatic cancers have RAS mutations. Cancers with RAS mutations have proved to be difficult to treat with current treatment, and there is a significant unmet medical need.

A follow-up review of clinical trials from the end of the 90'es indicates increased survival for patients treated with TG01. Some of these patients are still alive more than ten years later.
'/>"/>

SOURCE Targovax AS
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... 2014, regular quarterly dividend payment of $0.15 per share ... September 5, 2014, the record date. About ... of patents and royalty assets, consisting primarily of its ... with various biotechnology and pharmaceutical companies. PDL pioneered the  ...
(Date:9/15/2014)... Research and Markets has announced ... to 2020" report to their offering. ... has been receiving increasing amounts of scrutiny in recent ... clearly understood. For caregivers and their patients, the therapeutic ... mitigate exposure to cytotoxic drugs is clinical oncology, a ...
(Date:9/15/2014)... , Sept. 15, 2014 Research and ... Worldwide Market for In Vitro Diagnostic Tests, 9th Edition" ... covers the entirety of the clinical testing market and all ... Used by Top IVD Companies For Business Planning. ... based on the market events of 2013 and early 2014. ...
Breaking Medicine Technology:PDL BioPharma Completes Regular Quarterly Dividend Payment 2Closed Drug Transfer Systems to 2020 2Closed Drug Transfer Systems to 2020 3The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 3
... (NYSE: BSX ) will webcast its conference call ... 2011 on Thursday, July 28, at 8:00 a.m. ET. ... and Chief Executive Officer, and Jeff Capello, Executive Vice President ... the discussion will be available via Boston Scientific,s website.  Webcast ...
... July 14, 2011 /PRNewswire-Asia/ -- Owing to high-pressure life, ... fast food instead of traditional cooking, meanwhile, less and ... disadvantageous factors have affected people,s health . To ... just as its name implies, are the instruments used ...
Cached Medicine Technology:Boston Scientific to Webcast Conference Call Discussing Second Quarter 2011 Financial Results 2To Find the Key to Healthy Life 2
(Date:9/16/2014)... Registration is now open for the ... 10K, 5K, and 1-mile walk/run to be held on ... Local 338 RWDSU/UFCW, the Town of Babylon, and Island ... of Babylon Town Hall in Lindenhurst, NY. Registration is ... is organized by Hope For The Warriors®, a national ...
(Date:9/16/2014)... Alabama (PRWEB) September 16, 2014 *To find ... AL, visit Achieve Clinical Research on the web ( http://www.achieveclinical.com/trial/pneumonia-vaccine/ ... those who qualify:, There is no ... , Compensation may be provided for time ... pneumonia and influenza are the eighth leading cause of death ...
(Date:9/16/2014)... *Anyone who is interested in learning ... FL can visit Avail Clinical Research on the web ... 785-2404. , Why Are Volunteers Needed? , The common ... infecting mankind. While infections may not be as deadly ... more annual visits to the doctor than any other ...
(Date:9/16/2014)... justthoughtyoushouldknow.org , popular current events, ... new site today. The new site is better ... information easier to find, ingest, and share. , ... easy-to-read pages the information that we believe any ... retired college professor and founder of the site. ...
(Date:9/16/2014)... September 16, 2014 BQuick Nutrition is ... of its most popular products - BQuick BURN Clarinol ... educate the general public about the many benefits of ... building lean muscle mass. As well as having a ... benefits, supplement facts, and nutritional information - making it ...
Breaking Medicine News(10 mins):Health News:The Hope For The Warriors Long Island Run For The Warriors to Honor Wounded and Families of the Fallen 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 3Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 2Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 3Health News:JustThoughtYouShouldKnow.org Debuts New Website 2Health News:BQuick Nutrition Announces Newly Branded BURN Clarinol CLA Powder 2Health News:BQuick Nutrition Announces Newly Branded BURN Clarinol CLA Powder 3
... be promising news in the quest to find a ... (ALS), or Lou Gehrigs disease, scientists at the University ... shown that targeting neuronal support cells called astrocytes sharply ... in the laboratory of Don Cleveland, Ph.D., UCSD Professor ...
... to prove anecdotes that canines can smell dangerous drops in ... Irish researchers hope to prove that a dog,s keen sense ... blood sugar levels of diabetics. , Canines have already shown ... helping the physically disabled with daily tasks. , But researchers ...
... found that the gene ENPP1 is linked to preterm ... , Errol Norwitz, M.D., associate professor in the Department ... present preliminary results from this research at the Society ... in Dallas, Texas. , One out of eight babies ...
... Survey says latent infections among immigrants, minorities, poor thwart ... -- It appears that the United States will fall ... according to an analysis of National Health and Nutritional ... of latent TB infection (LTBI) in the U.S. population ...
... February 2, 2008 One-year data from a second ... given every 12 weeks provided sustained, clinically meaningful improvement ... through one year. According to findings presented at ... 87 percent of patients responding to ustekinumab 45 mg ...
... 1 Kristin Davis, star,of US hit TV show ... leading AIDS,activists at a Johannesburg press conference tomorrow, Saturday, ... and AIDS epidemic in,South Africa., (Photo: http://www.newscom.com/cgi-bin/prnh/20080201/LAF106-a ... http://www.newscom.com/cgi-bin/prnh/20080201/LAF106-b ) Kristin, ...
Cached Medicine News:Health News:Targeting astrocytes slows disease progression in ALS 2Health News:Dogs Could Be a Diabetic's Best Friend 2Health News:Dogs Could Be a Diabetic's Best Friend 3Health News:Dogs Could Be a Diabetic's Best Friend 4Health News:Gene linked to preterm birth among Hispanic women 2Health News:U.S. Unlikely to Meet Target for TB Elimination 2Health News:Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis 2Health News:Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis 3Health News:Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis 4Health News:'Sex & the City' Gets Serious About HIV and AIDS in South Africa - Kristin Davis Helps Oxfam Break the Stigma and Close the Treatment Gaps Fuelling AIDS 2Health News:'Sex & the City' Gets Serious About HIV and AIDS in South Africa - Kristin Davis Helps Oxfam Break the Stigma and Close the Treatment Gaps Fuelling AIDS 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: